EP1812048A4 - Gh-sekretagoga und ihre verwendung - Google Patents

Gh-sekretagoga und ihre verwendung

Info

Publication number
EP1812048A4
EP1812048A4 EP05797145A EP05797145A EP1812048A4 EP 1812048 A4 EP1812048 A4 EP 1812048A4 EP 05797145 A EP05797145 A EP 05797145A EP 05797145 A EP05797145 A EP 05797145A EP 1812048 A4 EP1812048 A4 EP 1812048A4
Authority
EP
European Patent Office
Prior art keywords
secretagogues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05797145A
Other languages
English (en)
French (fr)
Other versions
EP1812048A1 (de
Inventor
Thierry Abribat
Villers Andre De
Soraya Allas
Denis Gravel
Alcide Chapdelaine
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Theratechnologies Inc
Original Assignee
Theratechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA2485472A external-priority patent/CA2485472C/en
Priority claimed from US10/969,463 external-priority patent/US7316997B2/en
Application filed by Theratechnologies Inc filed Critical Theratechnologies Inc
Publication of EP1812048A1 publication Critical patent/EP1812048A1/de
Publication of EP1812048A4 publication Critical patent/EP1812048A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF] (Somatoliberin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
EP05797145A 2004-10-20 2005-10-20 Gh-sekretagoga und ihre verwendung Withdrawn EP1812048A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA2485472A CA2485472C (en) 2004-10-20 2004-10-20 Gh secretagogues and uses thereof
US10/969,463 US7316997B2 (en) 2003-05-29 2004-10-20 GH secretagogues and uses thereof
PCT/CA2005/001611 WO2006042408A1 (en) 2004-10-20 2005-10-20 Gh secretagogues and uses thereof

Publications (2)

Publication Number Publication Date
EP1812048A1 EP1812048A1 (de) 2007-08-01
EP1812048A4 true EP1812048A4 (de) 2012-01-18

Family

ID=36202645

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05797145A Withdrawn EP1812048A4 (de) 2004-10-20 2005-10-20 Gh-sekretagoga und ihre verwendung

Country Status (6)

Country Link
EP (1) EP1812048A4 (de)
JP (1) JP2008516994A (de)
KR (1) KR101228229B1 (de)
AU (1) AU2005297366B2 (de)
NO (1) NO20072136L (de)
WO (1) WO2006042408A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2508531B1 (de) 2007-03-28 2016-10-19 President and Fellows of Harvard College Geheftete Polypeptide
WO2008122118A1 (en) * 2007-04-04 2008-10-16 Theratechnologies Inc. Pharmaceutical formulations of ghrh molecules
CA2807685C (en) 2010-08-13 2020-10-06 Aileron Therapeutics, Inc. P53 derived peptidomimetic macrocycle
BR112013027150A2 (pt) 2011-04-21 2017-06-06 Theratechnologies Inc thera
TWI643868B (zh) 2011-10-18 2018-12-11 艾利倫治療公司 擬肽巨環化合物
MX362492B (es) 2012-02-15 2019-01-21 Aileron Therapeutics Inc Macrociclos peptidomiméticos.
US8987414B2 (en) 2012-02-15 2015-03-24 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
EP2914256B1 (de) 2012-11-01 2019-07-31 Aileron Therapeutics, Inc. Disubstituierte aminosäuren und verfahren zur herstellung und verwendung davon
SG10201902594QA (en) 2014-09-24 2019-04-29 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
AU2016235424A1 (en) 2015-03-20 2017-10-05 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458764B1 (en) * 1995-05-26 2002-10-01 Theratechnologies Inc. GRF analogs with increased biological potency
US6696063B1 (en) * 1998-12-30 2004-02-24 Applied Research Systems Ars Holding N.V. Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
US6518292B1 (en) * 1999-03-12 2003-02-11 Bristol-Myers Squibb Co. Heterocyclic aromatic compounds usefuls as growth hormone secretagogues
AU2003229222B2 (en) * 2003-05-29 2009-11-12 Theratechnologies Inc. GRF analog compositions and their use
US7893025B2 (en) * 2003-10-20 2011-02-22 Theratechnolgies Inc. Use of growth hormone releasing factor analogs in treating patients suffering from wasting

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; August 2003 (2003-08-01), ABRIBAT T ET AL: "TH9507, a growth hormone-releasing factor analogue (GRF), does not impair overall glucose control and decreases non-HDL cholesterol in patients with Type 2 diabetes.", XP002665112, Database accession no. PREV200400013130 *
See also references of WO2006042408A1 *

Also Published As

Publication number Publication date
AU2005297366B2 (en) 2011-12-08
KR101228229B1 (ko) 2013-01-31
AU2005297366A2 (en) 2006-04-27
KR20070069207A (ko) 2007-07-02
WO2006042408A9 (en) 2007-05-24
WO2006042408A1 (en) 2006-04-27
EP1812048A1 (de) 2007-08-01
NO20072136L (no) 2007-07-16
JP2008516994A (ja) 2008-05-22
AU2005297366A1 (en) 2006-04-27

Similar Documents

Publication Publication Date Title
IL265538B (en) Optimal variants of fc and their uses
EP1802588A4 (de) Substituierte aminopyrimidone und anwendungen davon
EP1756041A4 (de) Polykationische verbindungen und ihre verwendung
EP1781311A4 (de) Wachstumshormonsekretagoge
IL181670A0 (en) Substituted phenylaminothiazoles and use thereof
EP1539941A4 (de) Adzyme und deren verwendungen
IL213648A0 (en) OPTIMIZED Fc VARIANTS AND USES THEREOF
EP1824467A4 (de) Apogossypolon und dessen verwendungen
EP1812048A4 (de) Gh-sekretagoga und ihre verwendung
IL179497A0 (en) Carboranylporphyrins and uses thereof
IL181609A0 (en) Combination comprising zd6474 and imatinib
EP1791656A4 (de) Sieb und siebelement
HK1088837A1 (en) Clk-peptide and slk-peptide
EP1469860A4 (de) Antikrebskombination und deren verwendung
IL172195A0 (en) Thiotungstate analogues and uses thereof
PL2215908T3 (pl) 2-alkilo-cykloalk(en)ylo-karboksamidy i ich zastosowanie jako fungicydów
PL377770A1 (pl) Podstawione benzoksazynony i ich zastosowanie
IL180365A0 (en) Carboranylporphyrins and uses thereof
GB0428391D0 (en) Connection and connection part
ZA200702776B (en) Screen and screen element
GB0417345D0 (en) Substituted organopolysiloxanes and uses thereof
GB0420893D0 (en) Photosensitisers and their uses
IL165112A0 (en) Variant integrinpolypeptides and thereof
GB0417344D0 (en) Substituted organopolysiloxanes and use thereof
AU2003231827A8 (en) Pseudo-tissues and uses thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070502

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 3/00 20060101ALI20111208BHEP

Ipc: A61P 37/00 20060101ALI20111208BHEP

Ipc: A61K 38/25 20060101AFI20111208BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20111216

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20140305